Patient and Provider perspectives on long acting injectable ART

摘要 长效可注射抗逆转录病毒疗法（LAIART）预计将是治疗艾滋病的一个重大进展。 艾滋病毒感染的管理。然而，这种治疗创新将如何在患者中得到接受， 供应商仍然不清楚。目前，几乎没有什么数据可以用来预测，更不用说计划合并了 将这一艾滋病护理创新付诸实践。我们的初步研究表明， 参与这种ART管理模式的研究试验的参与者， 提供商通过拟议的研究，我们寻求更深入地了解人们的看法， 在美国不同的艾滋病病毒感染者群体及其护理提供者中，这种理解将 用于为LAI ART的推出提供信息，包括开发艾滋病毒感染者和提供者可以使用的工具 在选择治疗方案时指导共同决策。

ABSTRACT Long-acting injectable antiretroviral therapy (LAI ART) is anticipated to be a major advance in the management of HIV infection. However, how this therapeutic innovation will be received among patients and providers remains unclear. At present, there are few data with which to forecast, let alone, plan for incorporation of this innovation in HIV care into practice. Our preliminary studies demonstrate excitement for LAI ART among participants in research trials of this mode of ART administration, with possibly less enthusiasm among HIV care providers. With the proposed research studies, we seek to gain a deeper understanding of the perceptions regarding LAI ART among diverse groups of PLHIV in the US and their care providers. This understanding will be used to inform the roll-out of LAI ART, including the development of tools that PLHIV and providers can use to guide shared decision-making when choosing among treatment options.